Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2

Prostate

Volumn 68, Issue 6, 2008, Pages 610-619

  Tsui, Ke Hung ^a   Hsieh, Wen Chi ^b   Lin, Mei Hsien ^b   Chang, Phei Lang ^a   Juang, Horng Heng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

BTG2; LNCaP; PC 3; Proliferation; TRE; Triiodothyronine

Indexed keywords

ANDROGEN; LIOTHYRONINE; LIOTHYRONINE RECEPTOR; THYMIDINE; THYROID HORMONE RECEPTOR BETA; TRITIUM;

ARTICLE; B CELL TRANSLOCATION GENE 2; BINDING SITE; CARCINOMA CELL; CELL PROLIFERATION; CELL STRAIN LNCAP; CONSENSUS; DOWN REGULATION; GEL MOBILITY SHIFT ASSAY; GENE; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ADENOCARCINOMA; BASE SEQUENCE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HUMANS; IMMEDIATE-EARLY PROTEINS; MALE; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, THYROID HORMONE; TRANSCRIPTION FACTORS; TRIIODOTHYRONINE;

EID: 42949148063     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20725     Document Type: Article

References (43)

1. Cooke PS, Holsberger DR, Witorsch RJ, Sylvester PW, Meredith JM, Treinen KA, Chapin RE. Thyroid hormone, glucocorticoids, and prolactin at the nexus of physiology, reproduction, and toxicology. Toxicol Appl Pharmacol 2004;194:309-335.
2. Dunzendorfer U, Weber W, Russell DH. Polyandries, hydrolases, (PAP, LAP, SDH, plasmin) TSH, T3, T4 and C-peptide in benign hyperplasia of the prostate. Urol Res 1981;9:137-142.
3. Lehrer S, Diamond EJ, Bajwa AM, Kornreich R, Stagger S, Stone NN, Droller MJ, Stock RG. Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer. Prostate Cancer and Prostatic Dis 2001;4:232-234.
4. Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG. Serum triodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J Urol 2002;168:2431-2433.
5. Sakurai A, Nakai A, DeGroot LJ. Expression of three forms of thyroid hormone receptor in human tissues. Mol Endocrinol 1989;3:392-393.
6. Lazar MA. Thyroid hormone receptors: Multiple forms, multiple possibilities. Endocr Rev 1993;14:184-193.
7. Flamant F, Gauthier K, Samarut J. Thyroid hormones signaling is getting more complex: STORMS are coming. Mol Endocrinol 2007;21:321-333.
8. Bilek R, Gkonos PJ, Tavianini MA, Smyth DG, Roos BA. The thyrotrophin-releasing hormone (TRH)-like peptides in rat prostate are not formed by expression of the TRH gene but are suppressed by thyroid hormone. J Endocrinol 1992;132:177-184.
9. Howland BE, Ibrahim EA. Some effects of treatment with triiodothyronine (T3) on reproductive organ weights and gonadotropin levels in the serum and pituitary gland of the male rat. Horm Res 1974;5:193-198.
10. Mani Maran RR, Subramanian S, Rajendiran G, Sunil N, Archunan G, Arunakaran J, Govindarajulu P, Aruldhas MM. Prostate-thyroid axis: Stimulatory effects of ventral prostate secretions on thyroid function. Prostate 1998;36:8-13.
11. Hsieh ML, Juang HH. Cell growth effect of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl 2005;26:422-428.
12. Mamanasiri S, Yesil S, Dumitrescu AM, Liao XH, Demir T, Weiss RE, Refetoff S. Mosaicism of thyroid hormone receptor-beta gene mutation in resistance to thyroid hormone. J Clin Endocrinol Metab 2006;91:3471-3477.
13. Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ, Young CYF. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology 1999;140:1665-1671.
14. Zhu W, Young CY. Androgen-dependent transcriptional regulation of prostate-specific antigen gene by thyroid hormone 3,5,3′-L- triiodothyronine. J Androl 2001;22:136-141.
15. Tirone F. The gene PC3 (TIS21/BTG2), prototype member of the PC3/BTG/TOB family: Regulator in control of cell growth, differentiation, and DNA repair? J Cell Physiol 2001;187:155-165.
16. Rouault JP, Falette N, Guehenneux F, Guillot C, Rimokh R, Wang Q, Berthet C, Moyret-Lalle C, Savatier P, Pain B, Shaw P, Berger R, Samarut J, Magaud JP, Ozturk M, Samarut C, Puisieux A. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 1996;14:482-486.
17. Iacopetti P, Michelini M, Stuckmann I, Oback B, Aaku-Saraste E, Huttner WB. Expression of the antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that switch from proliferative to neuron-generating division. Proc Natl Acad Sci USA 1999;96:4639-4644.
18. Walden PD, Lefkowitz GK, Ficazzola M, Gitlin J, Lepor H. Identification of genes associated with stromal hyperplasia and glandular atrophy of the prostate by mRNA differential display. Exp Cell Res 1998;245:19-26.
19. Ficazzola MA, Fraiman M, Gitlin J, Woo K, Melamed J, Rubin MA, Walden PD. Antiproliferative B cell translocation gene 2 protein is down regulated posttranscriptionally as an early event in prostate carcinogenesis. Carcinogenesis 2001;22:1271-1279.
20. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 2002; 277:14877-14883.
21. Juang HH, Hsieh ML, Tsui KH. Testosterone modulates mitochondrial aconitase in the full-length human androgen receptor-transfected PC-3 prostatic carcinoma cells. J Mol Endocrinol 2004;33:121-132.
22. Juang HH. Nitroprudsside stimulates mitochondrial aconitase gene expression through the cyclic adenosine 3′-5′-monosphosphate signal transduction pathway in human prostate carcinoma cells. Prostate 2004;61:92-102.
23. Tsui KH, Chang PL, Juang HH. Zinc blocks gene expression of mitochondrial aconitase in human prostatic carcinoma cells. Int J Cancer 2006;118:609-615.
24. Williams GR, Bassett JHD. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab 2003;14:356-364.
25. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol 1995;109:105-111.
26. Duriez C, Falette N, Audoynaud C, Moyret-Lalle C, Bensaad K, Courtois S, Wang Q, Soussi T, Puisieux A. The human BTG2/TIS21/PC3 gene: Genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene 2002;282:207-214.
27. Prevot D, Morel AP, Voeltzel T, Rostan MC, Rimokh R, Magaud JP, Corbo L. Relationships of the antiproliferative proteins BTG1 and BTG2 with CAF1, the human homolog of a component of the yeast CCR4 transcriptional complex: Involvement in estrogen receptor alpha signaling pathway. J Biol Chem 2001;276:9640-9648.
28. Berthet C, Guehenneux F, Revol V, Samarut C, Lukaszewicz A, Dehay C, Dumontet C, Magaud JP, Rouault JP. Interaction of PRMT1 with BTG/TOB proteins in cell signalling: Molecular analysis and functional aspects. Genes Cells 2002;7:29-39.
29. Guardavaccaro D, Corrente G, Covone F, Micheli L, D'Agnano I, Starace G, Caruso M, Tirone F. Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. Mol Cell Biol 2000;20:1797-1815.
30. El-Ghissassi F, Valsesia-Wittmann S, Falette N, Duriez C, Walden PD, Puisieux A. BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells. Oncogene 2002;21:6772-6778.
31. Corrente G, Guardavaccaro D, Tirone F. PC3 potentiates NGF-induced differentiation and protects neurons from apoptosis. Neuroreport 2002;13:417-422.
32. Raouf A, Seth A. Discovery of osteoblast-associated genes using cDNA microarrays. Bone 2002;30:463-471.
33. Melamed J, Kernizan S, Walden PD. Expression of B-cell translocation gene 2 protein in normal human tissues. Tissue Cell 2002;34:28-32.
34. Rodier A, Marchal-Victorion S, Rochard P, Casas F, Cassar-Malek I, Rouault J-P, Magaud J-P, Mason DY, Wrutniak C, Cabello G. BTG1: A triodothyronine target involved in the myogenic influence of the hormone. Exp Cell Res 1999;249:337-348.
35. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, Getz G, Domany E, Givol D. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20:2225-2234.
36. Yoshida NL, Miyashita TUM, Yamada M, Reed JC, Sugita Y, Oshida T. Analysis of gene expression patterns during glucocorticoid-induced apoptosis using oligonucleotide arrays. Biochem Biophys Res Commun 2002;293:1254-1261.
37. Lin K-H, Zhu X-G, Shieh H-Y, Hsu H-C, Chen S-T, McPhie P, Cheng S-Y. Identification of naturally occurring dominant negative mutants of thyroid hormone alpha1 and beta1 receptors in human hepatocellular carcinoma cell line. Endocrinology 1994;137:4073-4081.
38. Nomura Y, Nagaya T, Tsukaguchi H, Takamatsu J, Seo H. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation. Endocrinology 1996;137:4082-4086.
39. Yamiya Y, Puzianowska-Yuznicka M, McPhie P, Nauman J, Chen S-Y, Nauman A. Expression of mutant thyroid hormone nuclear receptor is associated with human renal clear cell carcinoma. Carcinogenesis 2002;23:25-33.
40. Furuya F, Ying H, Zhao L, Cheng S-Y. Novel functions of thyroid hormone receptor mutants: Beyond nucleus-initiated transcription. Steroids 2007;72:171-179.
41. Forman BM, Yang C, Au M, Casanova J, Ghysdael J, Samuels HH. A domain containing a leucine-zipper-like motif mediates novel in vivo interactions between the thyroid hormone and retinoic acid receptors. Mol Endocrinol 1989;3:1610-1626.
42. Baumann CT, Maruvada P, Hager GL, Yen PM. Nuclear cytoplasmic shuttling by thyroid hormone receptors. J Biol Chem 2001;276:11237-11245.
43. Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgen. Biochem Biophys Res Commun 1990;173:534-540.